These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27566866)

  • 1. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
    Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.
    Licandro SA; Crippa L; Pomarico R; Perego R; Fossati G; Leoni F; Steinkühler C
    Skelet Muscle; 2021 Jul; 11(1):19. PubMed ID: 34294164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy.
    Giovarelli M; Zecchini S; Catarinella G; Moscheni C; Sartori P; Barbieri C; Roux-Biejat P; Napoli A; Vantaggiato C; Cervia D; Perrotta C; Clementi E; Latella L; De Palma C
    Pharmacol Res; 2021 Aug; 170():105751. PubMed ID: 34197911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Givinostat: First Approval.
    Lamb YN
    Drugs; 2024 Jul; 84(7):849-856. PubMed ID: 38967716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis and restore dystrophin in injured Duchenne dystrophic muscle.
    Xuan W; Khan M; Ashraf M
    Stem Cell Res Ther; 2021 Feb; 12(1):131. PubMed ID: 33579366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients.
    Mozzetta C; Sartorelli V; Steinkuhler C; Puri PL
    Trends Mol Med; 2024 Mar; 30(3):278-294. PubMed ID: 38408879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
    Spreafico M; Cafora M; Bragato C; Capitanio D; Marasca F; Bodega B; De Palma C; Mora M; Gelfi C; Marozzi A; Pistocchi A
    Pharmacol Res; 2021 Aug; 170():105750. PubMed ID: 34214631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic-pharmacodynamic analysis of givinostat.
    Fiorentini F; Germani M; Del Bene F; Pellizzoni C; Cazzaniga S; Rocchetti M; Bettica P
    Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):229-238. PubMed ID: 37306105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.
    Consalvi S; Saccone V; Mozzetta C
    Epigenomics; 2014; 6(5):547-60. PubMed ID: 25431946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.
    Arpan I; Willcocks RJ; Forbes SC; Finkel RS; Lott DJ; Rooney WD; Triplett WT; Senesac CR; Daniels MJ; Byrne BJ; Finanger EL; Russman BS; Wang DJ; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
    Neurology; 2014 Sep; 83(11):974-80. PubMed ID: 25098537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.
    Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L
    Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing drug effect from distributional data: A population approach with application to Duchenne Muscular Dystrophy treatment.
    Lavezzi SM; Rocchetti M; Bettica P; Petrini S; De Nicolao G
    Comput Methods Programs Biomed; 2019 Sep; 178():329-342. PubMed ID: 31416560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies.
    Sandonà M; Cavioli G; Renzini A; Cedola A; Gigli G; Coletti D; McKinsey TA; Moresi V; Saccone V
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy.
    Manning J; Kulbida R; Rai P; Jensen L; Bouma J; Singh SP; O'Malley D; Yilmazer-Hanke D
    Exp Physiol; 2014 Oct; 99(10):1370-86. PubMed ID: 24972834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.